
Background. Thermal ablation techniques, including radiofrequency ablation (RFA), microwave ablation (MWA), and laser ablation (LA), are increasingly used to treat benign thyroid nodules. Ultrasound-guided intermediate cervical plexus block (ICPB) has been investigated as an adjunct or alternative to local infiltration anesthesia (LIA). This narrative review examines its efficacy, safety, and clinical role. Methods. A focused literature search was conducted in PubMed/MEDLINE, Embase, Scopus, and Web of Science. Randomized and observational ablation studies and selected thyroid surgery studies were reviewed qualitatively. Results. Direct clinical evidence evaluating cervical plexus block during thyroid thermal ablation remains limited. A retrospective comparative study reported lower immediate postprocedural and 4-hour pain scores when cervical plexus block was added to perithyroidal local anesthesia and sedation, although quality-of-recovery scores and procedural duration were not significantly different. In a randomized controlled trial, ICPB combined with low-dose LIA provided intraoperative analgesia comparable to LIA alone, without demonstrating superiority. The trial also reported differences in selected postoperative symptoms and adverse events. Evidence from thyroid surgery is indirect and cannot be directly extrapolated to thyroid ablation. Overall, the available evidence does not establish the superiority of ICPB over LIA for intraoperative pain control. Conclusion. Ultrasound-guided ICPB may be a useful adjunct to local anesthesia in selected patients undergoing thermal ablation of benign thyroid nodules. Current evidence does not justify routinely replacing LIA. Anesthetic selection should consider procedural context, patient characteristics, and available expertise. Further comparative studies are needed to clarify its clinical benefits, safety, and optimal application protocols.
Background and objectives. Dyslipidemia remains a major modifiable determinant of atherosclerotic cardiovascular disease (ASCVD), yet many patients fail to achieve recommended lipid targets. This narrative review examined contemporary approaches to lipid assessment, cardiovascular risk stratification, established lipid-lowering treatments, and emerging precision therapies. Methods. PubMed and Scopus were searched for studies published from 2017 through 2026 using terms related to dyslipidemia, lipid biomarkers, cardiovascular risk, lipid-lowering therapies, and emerging treatments. Publications were prioritized according to clinical relevance, methodological quality, and contribution to guideline recommendations or treatment efficacy and safety. Findings were qualitatively synthesized. No meta-analysis was performed. Results. LDL-C remained the principal therapeutic target, with ApoB, non-HDL cholesterol, and lipoprotein(a) providing complementary information in selected clinical settings. Statins, ezetimibe, bempedoic acid, and PCSK9 monoclonal antibodies have evidence supporting cardiovascular outcome benefits in defined populations. Inclisiran provides substantial LDL-C lowering, but cardiovascular outcome evidence remains pending. Obicetrapib has demonstrated lipid-lowering efficacy, whereas cardiovascular benefit has not been established. Lp(a)-targeted drugs and gene-editing approaches remain investigational. Notably, the phase 3 Lp(a)HORIZON trial of pelacarsen did not meet its primary cardiovascular outcome endpoint in topline results reported in 2026. Conclusions. Contemporary dyslipidemia management combines risk-guided LDL-C lowering with complementary biomarkers and sustained reduction of lifetime exposure to atherogenic lipoproteins. Treatment decisions should distinguish therapies with demonstrated cardiovascular outcome benefits from agents whose evidence currently supports lipid lowering alone.
Background. Necrotic variants of leprosy reactions, specifically Lucio phenomenon (LP) and necrotic erythema nodosum leprosum (nENL), represent severe, potentially life-threatening manifestations of Hansen's disease. These conditions may involve vascular damage, thrombosis, and extensive cutaneous necrosis, although their underlying mechanisms differ. Aim. This review describes the clinical characteristics, geographical distribution, and reported management approaches for LP and nENL between 2019 and 2026. Methodology. An extensive literature survey was conducted across PubMed, ScienceDirect, and EMBASE using keywords related to Hansen's disease and atypical manifestations, including “necrotic,” “ulcerative,” “Lucio phenomenon,” and “vasculonecrotic.” Inclusion criteria focused on primary clinical evidence, including case reports and case series, published from January 2019 to March 2026. Results. The compiled table contains 66 clinical entries from 21 countries. India and Indonesia account for 31 entries (47.0%). Clinical manifestations included punched-out necrotic ulcers, stellate plaques, and hemorrhagic bullae. Although high bacillary indices (BI 5+ to 6+) were frequently reported, severe reactions also occurred at lower indices. Management approaches included multidrug therapy, systemic corticosteroids, and, in selected patients, thalidomide. Surgical debridement was required in some cases with extensive tissue necrosis, while anticoagulants were reported in selected cases with thrombotic complications. Conclusion. Early recognition of LP and nENL is critical, particularly in nonendemic regions where these manifestations may resemble other forms of vasculitis. Appropriate diagnosis and individualized management are essential in reducing complications and improving clinical outcomes.
Background and objectives. Risk stratification in patients with acute coronary syndrome (ACS) remains challenging, particularly in clinical settings where conservative management without revascularization is the primary treatment pathway. This study evaluated the prognostic utility of the red cell distribution width-to-high-density lipoprotein cholesterol ratio (RHR), red cell distribution width (RDW), and high-density lipoprotein cholesterol (HDL-C) in assessing outcomes among ACS patients managed conservatively. Materials and methods. A prospective cohort study was conducted between July and October 2024 at a tertiary referral hospital in Banda Aceh, Indonesia. Eighty-two ACS patients managed without revascularization were followed for three months to ascertain the development of major adverse cardiovascular events (MACE). Baseline RDW and lipid profiles were obtained to calculate RHR. Predictive performance was assessed using receiver operating characteristic (ROC) curves, and adjusted associations were examined using multivariable logistic regression. Results. MACE occurred in 47.6% (n = 39) of the cohort. An RHR cut-off of ≥0.375 demonstrated a moderate discriminatory area under the curve (AUC = 0.699). In unadjusted bivariate analysis, both elevated RHR and low HDL-C (<33.5 mg/dL) were significantly associated with higher odds of MACE (crude OR = 4.21, 95% CI: 1.62–10.97, p = 0.003; and crude OR = 3.69, 95% CI: 1.34–10.15, p = 0.011, respectively), whereas high RDW alone (≥14.85%) showed no significant association (crude OR = 2.62, p = 0.115). However, in multivariable logistic regression adjusting for RHR and HDL-C, these associations lost statistical significance (RHR adjusted OR = 2.66, 95% CI: 0.75–9.48, p = 0.132; HDL-C adjusted OR = 1.95, 95% CI: 0.57–6.64, p = 0.286). Conclusions. Elevated RHR is associated with three-month MACE in this conservatively managed ACS cohort. Although the adjusted association was not statistically significant in the multivariable model, RHR may represent a potentially useful, readily available exploratory prognostic marker.
Secondary cardiac lymphoma (SCL) is a rare manifestation of systemic lymphoma, most commonly involving the pericardium and typically associated with diffuse large B-cell lymphoma (DLBCL). We report the case of a 75-year-old man with newly diagnosed stage IIIB DLBCL (non-GCB phenotype) who initially achieved complete metabolic remission after R-CHOP chemotherapy. However, early relapse occurred within three months, prompting second-line treatment with R-GEMOX. Follow-up 18F-FDG PET/CT revealed disease progression with intense hypermetabolic activity in mediastinal and hilar lymph nodes, new uptake in the pericardial recess suggestive of pericardial lymphomatous involvement, and suspicious rectal wall involvement. The patient developed worsening dyspnea and rectal bleeding; rectoscopy and subsequent biopsy confirmed lymphomatous infiltration of the rectal wall. This case illustrates the aggressive nature of relapsed DLBCL and the value of metabolic imaging in detecting suspected involvement of uncommon extranodal sites.